ABSTRACT
Maintaining agro-food product safety remains a significant challenge for satisfying local and global consumers in tropical countries. This issue has been growing due to new pathogen strains, low infectious doses, increased virulence, antibiotic resistance, cross-contamination or recontamination of foods, food-contact surfaces, and biocontamination of water within the food production chain. To respond to this situation, we studied the inactivation efficacy of surface dielectric barrier discharge (SDBD) plasma against pathogens on the surface of various pork cut parts, including the loin, hip, belly, liver, and intestine. The SDBD plasma was operated at 0.30 W/cm2 in ambient air, with a gap of 5.0 mm between the plasma generator and the sample surface. Up to 96% germicidal efficiency against surface pathogens were observed, showing after 1 min of SDBD plasma exposure. Visualization of reactive species deposition on the treated surface using KI-starch agar gel reagent indicated a non-uniform distribution of the SDBD-generated reactive species on the treated surface. Following the indirect plasma treatment by the SDBD reactor, the overall color of pork cut samples after plasma treatment was significantly different compared with before. However, the surface morphology and structural characterization of the treated pork cut samples were not significantly altered, and residual nitrites and nitrates were lower than the restriction level for safe consumption. The SDBD reactor should be developed further to produce a uniform distribution of reactive species on the meat surface for the improvement of the decontamination effect without undesirable effects on meat quality parameters.
ABSTRACT
Dihydroartemisinin-piperaquine is an effective drug in the treatment of Plasmodium falciparum and P. vivax malaria. The objective of this study was to evaluate the population pharmacokinetics and pharmacodynamics of piperaquine in patients with P. vivax malaria in Thailand after a standard regimen of dihydroartemisinin-piperaquine to determine whether residual piperaquine prevents or delays the emergence of P. vivax relapse. Sparse blood samples were collected from 116 patients. Piperaquine pharmacokinetics were described well by a three-compartment distribution model. Relapsing P. vivax malaria was accommodated by a constant baseline hazard (8.94 relapses/year) with the addition of a surge function in a fixed 3-week interval and a protective piperaquine effect. The results suggest that a large proportion of the first relapses were suppressed completely by residual piperaquine concentrations and that recurrences resulted mainly from emergence of the second or third relapse or from reinfection. This suggests a significant reduction in P. vivax morbidity when using dihydroartemisinin-piperaquine compared with other antimalarial drugs with shorter terminal postprophylactic effects.
